Eureka Alert
Share

LONDON, ON – Personalized medicine is the analysis of a patient’s DNA to predict how they will respond to medications. Led by Dr. Richard Kim, scientist at Lawson Health Research Institute (Lawson) and clinical pharmacologist at London Health Sciences Centre (LHSC), researchers at Lawson have received $4.4 million to study an expanded personalized medicine program at LHSC. One third of the funding comes from the provincial government’s Ontario Research Fund (ORF) while the remainder is contributions from Thermo Fisher Scientific and donor funding through London Health Sciences Foundation.

Personalized medicine uses pharmacogenomics – the study of genetic changes that alter the way a person responds to individual drugs. The new funding will enable researchers to follow patient outcomes and assess the cost-effectiveness of LHSC’s personalized medicine program, providing evidence on the relationship between the cost of the program and how patient care is improved.

LHSC’s personalized medicine program involves full integration of research into patient care. Research questions are informed by the therapeutic challenges seen in hospital. As research discoveries are made, they are then applied back to patient care. LHSC was the first in Canada to implement personalized medicine as a clinical strategy. The practice began in 2008

read more...


Article originally posted at
www.eurekalert.org

Click here for the full story


CategoryAggregator News

© 2017 - LIFE EXTENSION ADVOCACY FOUNDATION
Privacy Policy / Terms Of Use

Powered by MMD